Catalent Inc
NYSE:CTLT
Catalent Inc
Capital Expenditures
Catalent Inc
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Catalent Inc
NYSE:CTLT
|
Capital Expenditures
$-437m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-15%
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
$-4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
$-1.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
$-3.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
$-3.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
$-7.4B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-21%
|
See Also
What is Catalent Inc's Capital Expenditures?
Capital Expenditures
-437m
USD
Based on the financial report for Dec 31, 2023, Catalent Inc's Capital Expenditures amounts to -437m USD.
What is Catalent Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-15%
Over the last year, the Capital Expenditures growth was 38%. The average annual Capital Expenditures growth rates for Catalent Inc have been 13% over the past three years , -20% over the past five years , and -15% over the past ten years .